Genentech Takes Over GlycArt Anti-CD20 Antibody Work
This article was originally published in The Pink Sheet Daily
Executive Summary
Enhanced antibody may work better than standard of care in blood cancers.
You may also be interested in...
Roche Reports Rituxan Survival Data For CLL But Has Captured U.S. Market Before Approval
Adding Rituxan (rituximab) to standard chemotherapy for previously untreated chronic lymphocytic leukemia patients gives them an unprecedented overall survival advantage, but the headline data, presented at the American Society of Hematology meeting in New Orleans Dec. 7, likely won't do much to grow Roche's U.S. bottom line
Roche Reports Rituxan Survival Data For CLL But Has Captured U.S. Market Before Approval
Adding Rituxan (rituximab) to standard chemotherapy for previously untreated chronic lymphocytic leukemia patients gives them an unprecedented overall survival advantage, but the headline data, presented at the American Society of Hematology meeting in New Orleans Dec. 7, likely won't do much to grow Roche's U.S. bottom line
Xencor Set To Spruce Up Pfizer Antibodies
Pfizer gains wide access to test-drive antibody-enhancing tools via new licensing deal.